ImageneBio Inc
imagenebio.comWhat Do They Do?
Develops an experimental antibody treatment for people with atopic dermatitis and other immune, autoimmune and inflammatory diseases.
10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory…View ↗
How Do They Make Money?
Companies may pay upfront to license its intellectual property, with additional payments tied to development, regulatory or commercial milestones and royalties on sales of approved products. Collaboration partners may also fund research, development and clinical materials.
10-K for FY2025, filed Mar 10, 2026The principal activities from which the Company generates revenue include licensing agreements and collaboration agreements. License…View ↗
$800K
-
10-K for FY2025, filed Mar 10, 2026
$800K ↗
Who Are Their Customers?
Other companies license its intellectual property or collaborate on research, development and commercialization of product candidates.
10-K for FY2025, filed Mar 10, 2026The principal activities from which the Company generates revenue include licensing agreements and collaboration agreements. License…View ↗
Do Revenues Turn Into Profits?
No. It lost $45.3M in FY2025.
10-K for FY2025, filed Mar 10, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$10.2MView ↗
- ▲ +34% (Loss)
- vs −$7.6M in Q2 FY2025
-
Jul 23, 2026
Appointed Yanina Grant-Huerta as chief financial officer
She became chief financial officer and principal financial officer effective July 20, 2026.
Sources
8-K, filed Jul 23, 2026
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Kristin Yarema, Ph.D.…View ↗
Shrinking. Revenue fell 97% in 4 years, from $31M in FY2021 to $800K in FY2025, about 60% a year.
From cancer drugs to inflammatory disease
The earlier report described targeted cancer drug candidates across multiple pathways; the current report centers on an antibody for autoimmune and inflammatory diseases, initially atopic dermatitis.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 10, 2026We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs.…View ↗
We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory…View ↗
Who Do They Compete With?
Competes with Sanofi, Regeneron, Leo Pharmaceuticals, Eli Lilly, Galderma Laboratories, Pfizer, AbbVie, Nektar Therapeutics, Apogee Therapeutics, Kymera Therapeutics, Aclaris Therapeutics, Corvus Pharma, UCB Pharma, Amgen, Kyowa Kirin, Abcellera, Astria, and Navigator Medicines
10-K for FY2025, filed Mar 10, 2026There are several approved products for moderate-to-severe AD, such as DUPIXENT® (dupilumab), an IL-4Ra mAb marketed by Sanofi/Regeneron…View ↗
Loading...
